Evaluation of Efficacy and Safety of Recombinant Sperm-Specific Contraceptive Vaccine in Albino Mice
Article first published online: 14 FEB 2013
© 2013 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 69, Issue 5, pages 495–508, May 2013
How to Cite
Evaluation of efficacy and safety of recombinant sperm-specific contraceptive vaccine in albino mice. Am J Reprod Immunol 2013; 69: 495–508., , , , .
- Issue published online: 12 APR 2013
- Article first published online: 14 FEB 2013
- Manuscript Received: 3 JAN 2013
- Manuscript Accepted: 3 JAN 2013
This study was undertaken to evaluate the efficacy and safety of recombinant SP-10 protein for male contraception.
Methods of study
Adult male mice were divided into five groups. Group I was placebo-treated control while Groups II–V were immunized with recombinant SP-10 protein on day 0 and 21 with different doses (range 25–100 μg). From each Group, animals were put for mating fertility test. Histological and hematological parameters, sperm characteristics, serum clinical biochemistry and testosterone levels were investigated.
Group I showed normal fertility. Group II–V showed dose dependent reduction in fertility. In contrast, at higher dose (75 and 100 μg), all animals were sterile for three months. Further, all parameters under investigation in experimental groups were comparable to those of control animals.
Our study has put forth a proof of concept for male contraception for the first time, which may be considered suitable for contraceptive vaccine development.